Berobenatide

Pfizer's obesity drug shows potential for monthly dosing

Mid-stage study data reveals Pfizer's experimental obesity drug, berobenatide, could achieve significant weight loss with a groundbreaking monthly dosing schedule, a stark contrast to current weekly o